1-10 of 10
Revolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
CME/CERevolutionizing Care for Patients With T2D and Obesity: From Pathophysiology to Personalized Treatments
GLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
ObesityGLP-1RA for CVD risk reduction in obesity and overweight - Clinical implications
GLP-1RA reduces risk of CV events associated with overweight and obesity
ObesityGLP-1RA reduces risk of CV events associated with overweight and obesity
Improvement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
ObesityImprovement in health outcomes with GLP-1RA in patients with overweight or obesity with CVD
Healthy lifestyle interventions for CVD risk reduction in secondary prevention
ObesityHealthy lifestyle interventions for CVD risk reduction in secondary prevention
- advertisement
Main messages of new ESC guidelines for CVD management in diabetes
ObesityMain messages of new ESC guidelines for CVD management in diabetes
Clinically meaningful benefits with GLP-1RA in HFpEF and obesity
ObesityClinically meaningful benefits with GLP-1RA in HFpEF and obesity
Timing of benefits of intentional weight loss in cardiometabolic disease
ObesityTiming of benefits of intentional weight loss in cardiometabolic disease
An urgent call for action to tackle excess adiposity
ObesityAn urgent call for action to tackle excess adiposity
- advertisement
